News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
Innocoll (INNL) Announces The Completion Of Enrollment In Two Pivotal Phase III Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections 6/23/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 6/20/2016
GlaxoSmithKline (GSK)'s Lung Drug Passes Phase III Test 6/20/2016
Circassia (CIR.L) Stock Crashes as Allergy Drug Flunks Crucial Phase III Study 6/20/2016
Can-Fite BioPharma (CFBI) Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects 6/16/2016
IBSA Release: Prescription Chondroitin Sulphate Is As Efficacious As Celecoxib And Better Than Placebo In Knee Osteoarthritis 6/14/2016
Novo Nordisk Canada Inc. (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba(1c) In Type 1 Diabetes And A Comparable HbA(1c) Reduction In Type 2 Diabetes Versus NovoRapid (Insulin Aspart) 6/14/2016
Sanofi (SNY)'s New Diabetes Combo Nails Late-Stage Goals 6/13/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Janssen-Cilag International NV (JNJ) Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
Bristol-Myers Squibb Canada (BMY) Release: Canada's Health Technology Assessment Agency Gives Positive Recommendation For OPDIVO To Treat Non-Small Cell Lung Cancer 6/9/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study 6/8/2016
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease 6/8/2016
Samsung Bioepis Announces New Data On Three Anti-TNF--a Biosimilar Molecules At The Annual European Congress On Rheumatology (EULAR 2016) 6/8/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101) 6/7/2016
ASCO2016: Mylan (MYL)-BioCon (BIOCON.NS)'s Biosimilar Cancer Drug Comparable to Roche (RHHBY)'s Herceptin 6/6/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
Merck & Co. (MRK) Partners With Array BioPharma (ARRY) And Pierre Fabre To Initiate BRAF-Mutant CRC Phase III Trial 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: Janssen Pharmaceutical Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Astellas (ALPMY) And Medivation (MDVN) Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer 6/2/2016
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016
Theravance Biopharma (TBPH) Completes Enrollment In All Three Phase 3 Clinical Studies Of Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 6/2/2016
Nektar Therapeutics (NKTR), DAIICHI SANKYO EUROPE GmbH Strike $80 Million+ ONZEALD Pact 6/1/2016
Can-Fite BioPharma (CFBI) Reaches Agreement With European Medicines Agency On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis 6/1/2016
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016
Helsinn Group To Present At ASCO Pooled Follow Up Efficacy Data Analysis From Two Phase III Studies For Anamorelin In Cachectic Patients With Non-Small Cell Lung Cancer (NSCLC) 6/1/2016
Daiichi Sankyo, Inc. (DSNKY) Not Proceed With Lung Cancer Study 5/31/2016
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance 5/31/2016
Innocoll (INNL)'s Painkiller Passes Final Phase III Tests, Heads for 2017 Launch 5/25/2016
SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting 5/24/2016
Shionogi Release: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
Norgine Release: New Positive Phase III Study For NER1006 - The First 1 Litre PEG-Based Bowel Preparation 5/24/2016
After Initial Miss, GlaxoSmithKline (GSK)'s Pioneering Lung Study Shows Positive Results 5/24/2016
FDA Questions Study Findings, Practicality of Novo Nordisk A/S (NVO)'s Diabetes Drug Ideglira 5/23/2016
Genmab A/S (GEN.CO) Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 5/19/2016
AstraZeneca PLC (AZN)'s Gastric Cancer Drug Lynparza Flunks Phase III Test 5/18/2016
AstraZeneca PLC (AZN)'s Asthma Drug Hits Phase III Goal, Predicted to Reach Market in 2017 5/18/2016
European Scleroderma Trial Investigating Cytori Therapeutics (CYTX) Cell Therapy To Be Presented In Japan 5/17/2016
SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec 5/16/2016
Theravance Biopharma (TBPH) Release: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV (Telavancin) As A Treatment For Staphylococcus Aureus HABP/VABP, Including Cases Caused By MRSA 5/16/2016
OncoGenex (OGXI) Reports Financial Results For First Quarter 2016 5/13/2016
Hutchison China MediTech (Chi-Med) Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib in Colorectal Cancer 5/13/2016
Theravance Biopharma (TBPH) To Present New Data Analyses From Phase 3 ATTAIN Trials Of VIBATIV (Telavancin) In Treatment Of HABP/VABP At American Thoracic Society 2016 International Conference 5/12/2016
Santen Europe Release: Vekacia (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary And Key Secondary Endpoints 5/11/2016
Allergan (AGN) And Gedeon Richter (RIG2.F) Announce Positive Phase III Results For Ulipristal Acetate 5 And 10 Mg In The Treatment Of Uterine Fibroids 5/9/2016
DelMar Pharma Announces $5.6 Million Private Placement Of Preferred Shares 5/5/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/3/2016
Intec Pharma Ltd. Appoints VP Of Clinical And Regulatory Affairs 5/3/2016
Can-Fite BioPharma (CFBI) To Present Data On Cf602 In The Treatment Of Erectile Dysfunction At American Urological Association's Annual Meeting 5/2/2016
Elekta Release: New Data Presented At ESTRO 35 Show Positive Cosmesis And Favorable Late Side Effects After Accelerated Partial Breast Irradiation (APBI) With Multicatheter Interstitial Brachytherapy 5/2/2016
Can-Fite BioPharma (CFBI) To Present At Joseph Gunnar & Co.'s Pioneers 2016 Conference In New York City On May 5, 2016 4/29/2016
Novartis AG (NVS) Granted Three Breakthrough Badges for Ilaris 4/27/2016
DalCor Randomizes First Patient In The DalGenE Phase 3 Cardiovascular Outcomes Trial 4/26/2016
JAMA Publishes Phase III Data From Allergic Asthma Trial With ALK-Abello A/S's House Dust Mite SLIT-Tablet, ACARIZAX 4/26/2016
PHARNEXT Announces The Opening Of The First U.S. Study Site For Its PLEO-CMT International Pivotal Phase 3 Trial In Charcot-Marie-Tooth Disease Type 1A 4/25/2016
Merck KGaA (MKGAF.PK) Release: Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone 4/25/2016
Genmab A/S (GEN.CO) Announces Daratumumab Data To Be Presented At 2016 ASCO Annual Meeting 4/20/2016
Basilea (BSLN.SW) Wins $100 Million Contract to Fund Phase III Ceftobiprole Program 4/20/2016
Teva (TEVA) Presents New Data For SD-809 In Huntington Disease At 68th American Academy of Neurology Annual Meeting In Vancouver, B.C. 4/18/2016
AbbVie (ABBV) Announces Real-World Data With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) And EXVIERA (Dasabuvir Tablets) From Large German Hepatitis C-Registry 4/15/2016
Medivir (MVRBF): New Data For Simeprevir Will Be Presented At Easl's International Liver Congress 2016 4/11/2016
Addex Therapeutics (ADXN.SW) Reports Positive Results Of An mGlu5 Receptor Occupancy Study With Dipraglurant In Healthy Volunteers 4/11/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016
CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI (enzalutamide) 4/7/2016
Axovant (AXON) To Present At The Goldman, Sachs & Co. Alzheimer's Symposium 4/5/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma 4/5/2016
Merck & Co. (MRK) And Pfizer (PFE) Announce First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma 4/5/2016
Braeburn Pharma And Camurus Announce Enrollment Goals Reached In Two Pivotal Phase 3 Trials Of CAM2038 For Treatment Of Opioid Dependence 4/5/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Tops Teriparatide in Phase III Osteoporosis Study 4/4/2016
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On April 4-6, 2016 In Stockholm, Sweden 4/4/2016
Chugai Pharma Europe Announces Positive Phase III Results Of Aplidin 4/4/2016
Onxeo Announces Positive DSMB Recommendation To Continue Livatag Relive Study In HCC 4/4/2016
Taiho Pharma's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Phase III TERRA Study In Asian Patients With Refractory Metastatic Colorectal Cancer 4/1/2016
Specialised Therapeutics Asia Release: Novel Multiple Myeloma Drug Aplidin Shows Positive Results In Pivotal Phase 3 Study 3/31/2016
Auris Medical AG (EARS) Completes Enrollment Of TACTT2 Phase 3 Trial Of AM-101 In Acute Inner Ear Tinnitus 3/30/2016
Mezzion (140410.KQ) Receives Special Protocol Assessment (SPA) Agreement From FDA For Udenafil Phase 3 Studies In Adolescents With Single Ventricle Congenital Heart Disease With Fontan Physiology 3/24/2016
Medivation (MDVN) Release: Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer 3/24/2016
Advanced Accelerator Applications Provides Lutathera Update 3/23/2016
Mologen AG (MOLGF.PK): All Key Milestones Achieved In 2015 3/22/2016
Acacia Pharma Initiates Second Pivotal Phase 3 Treatment Study With Baremsis (APD421) In Post-Operative Nausea & Vomiting (PONV) 3/21/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Shines in Phase III Osteoporosis Trial 3/21/2016
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July 3/21/2016
Janssen Research & Development Release: STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy 3/18/2016
Heart Metabolics Limited Announces Multiple Senior Appointments To Management Team 3/15/2016
GW Pharma (GWPH) Shares Double as Cannabis Drug Meets Goals in Phase III Study 3/15/2016
Regeneron (REGN), Sanofi (SNY)'s RA Drug Beats AbbVie (ABBV)'s Blockbuster Humira in Phase III Study 3/14/2016
PTC Therapeutics (PTCT) Provides Update On Health Canada Review Of Translarna (ataluren) For The Treatment Of Duchenne Muscular Dystrophy 3/14/2016
OncoGenex (OGXI) Reports Financial Results for Year End 2015 3/10/2016
TRANSGENE (ENX:TNG) Reports 2015 Financial Results And Provides Outlook For 2016 3/8/2016
Novo Nordisk A/S (NVO) Release: Victoza Significantly Reduced The Risk Of Major Adverse Cardiovascular Events In The LEADER Trial 3/7/2016
Celsion (CLSN) Announces Launch Of The OPTIMA Study In China 3/7/2016
Biofrontera AG Announces Full Results Of Phase III Clinical Trial Evaluating BF-200 ALA For Treatment Of Basal Cell Carcinoma (BCC) 3/7/2016
Green Cross Biotherapeutics Receives Health Canada Approval For Phase III Clinical Trials Of IVIG 10% 3/7/2016
Newron Pharmaceuticals (NWRN) Reports 2015 Financial Results 3/1/2016
AbbVie (ABBV) Receives European Medicines Agency Orphan Drug Designation For Investigational Compound Venetoclax For The Treatment Of Acute Myeloid Leukemia (AML) 2/26/2016
Eli Lilly (LLY) Receives Positive CHMP Opinion For Ixekizumab For The Treatment Of Moderate-To-Severe Plaque Psoriasis 2/26/2016
AbbVie (ABBV) Receives CHMP Positive Opinion For VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis (Child-Pugh A) In Europe 2/26/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal 2/26/2016
PolyPid Ltd. Announces Completion Of $22 Million Series D Financing 2/24/2016
Helsinn Announces Publication Of Anamorelin ROMANA 1 And ROMANA 2 Phase III Studies In The Lancet 2/23/2016
Sirtex Medical (SRX.AX) Release: SIRFLOX Study Published In Journal Of Clinical Oncology 2/23/2016
Novartis AG (NVS)'s Leukemia Drug Gets Breakthrough Designation, Same Week as AstraZeneca PLC (AZN) and Roche (RHHBY) Drugs 2/22/2016
OBI Pharma (SHPG) Reports Topline Results From OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial In Patients With Metastatic Breast Cancer 2/22/2016
OSE Pharma: First Patients Enrolled And Dosed In The Pivotal Trial Of Phase III Of The Immunotherapy Tedopi For Advanced Non-Small Cell Lung Cancer 2/22/2016
Jazz Pharma (JAZZ) To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting 2/18/2016
Roche (RHHBY)'s Multiple Sclerosis Drug Gets Breakthrough Status, Likely to Haunt Biogen (BIIB) 2/18/2016
Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy And Excellent Safety For BF-200 ALA Treatment Of Superficial Skin Cancer 2/11/2016
Chugai Pharma's Alecensa Trial Stopped Early After Successfully Meeting Primary Endpoint 2/11/2016
Transition Therapeutics (TTH.TO) Announces Second Quarter Fiscal 2016 Financial Results 2/10/2016
Alkermes (ALKS) Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia 2/10/2016
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation 2/8/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Ascendis Pharma A/S To Present At The Leerink Partners Global Healthcare Conference 2/4/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
OSE Pharma Announces U.S. Initiation Of Atalante 1, The Company’s Global, Pivotal Phase III Trial For Tedopi Immunotherapy In Non-Small Cell Lung Cancer 2/4/2016
Steba Biotech Announces Positive Top-Line Results From Its Latin American Phase 3 Clinical Trial Of TOOKAD In Patients With Localized Prostate Cancer And Obtains First Marketing Authorization In Mexico 2/1/2016
Allergan (AGN)'s Rapastinel Snags Breakthrough Tag from the FDA for Depression 1/29/2016
Valeant (VRX) Announces FDA Acceptance Of BLA Submission For Brodalumab In Moderate-To-Severe Plaque Psoriasis 1/25/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
Steba Biotech Completes Its European Phase 3 Clinical Trial Of TOOKAD In Patients With Low-Risk Prostate Cancer And Submits Marketing Authorization Application To The European Medicines Agency 1/25/2016
Stock Craters as Alkermes (ALKS)' Depression Drug Fails in Two Late-Stage Trials 1/22/2016
Allergan (AGN) Release: VIBERZI (eluxadoline) Phase III Trial Results Published In The New England Journal of Medicine 1/21/2016
AbbVie (ABBV) and Roche (RHHBY)'s Venetoclax Snags Breakthrough Tag from the FDA for Blood Cancer 1/20/2016
AEterna Zentaris (AEZS) Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase III Trial Of Macrilen 1/19/2016
Glioblastoma Treatment Market Will Expand to $3.3 Billion by 2024, GlobalData Report Says 1/14/2016
CrystalGenomics Partners With TR-Pharm For Acelex Commercialization In Turkey And MENA 1/12/2016
Cardiorentis Bags $60 Million and Adds Two Key Senior Execs to the Roster 1/11/2016
TiGenix Announces Acceptance Of Cx601 Abstract For Presentation At ECCO 2016 Congress 1/11/2016
Regeneron (REGN) And Sanofi (SNY) Announce Sarilumab Biologics License Application Accepted For Review By US FDA 1/8/2016
ViiV Healthcare To Progress Collaboration With Janssen To Develop The First Long-Acting, Two Drug Injectable Regimen For Treatment Of HIV-1 Infection 1/7/2016
Vtesse, Inc. Announces FDA's Granting Of Breakthrough Therapy Designation For VTS-270 In Niemann-Pick Type C1 Disease 1/6/2016
OSE Pharma Announces Initiation Of Its Pivotal Phase 3 trial Of Tedopi In Non-Small Cell Lung Cancer 1/6/2016
Acacia Pharma Announces Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In Prevention Of Post-Operative Nausea & Vomiting 1/5/2016
Pfizer (PFE)'s Pristiq Fails to Beat Placebo in Phase III MDD Study 12/23/2015
Kamada Ltd. (KMDA)'s Rabies Drug KamRab Meets Phase II/III Primary Endpoint 12/23/2015
BeyondSpring Pharmaceuticals Granted CTA By CFDA To Initiate China Arm Of Global Phase III Trial Of Lead Asset Plinabulin 12/22/2015
Merck KGaA (MKGAF.PK), Pfizer (PFE) Accelerate Immuno-Oncology Drug Avelumab into Phase III Ovarian and Bladder Cancer Trials 12/22/2015
Kitov (KTOV) Reports Additional Data From Its Phase III Trial On The Beneficial Blood Pressure Effects Of KIT-302 12/18/2015
Hutchison China MediTech (Chi-Med) Release: Initiation Of Sulfatinib Phase III Registration Study In Neuroendocrine Tumor Patients 12/18/2015
Celyad Announces The Publication Of Its CHART-1 Trial Design Methods Paper In The European Journal Of Heart Failure 12/16/2015
Braeburn Pharma And Camurus Announces Start Of Phase 3 Trial Of Long-Acting Buprenorphine Treatments For Opioid Dependence 12/15/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Initiate Two Phase III Studies Of Investigational Immunotherapy Avelumab In Advanced Gastric And Gastro-Esophageal Junction Cancers 12/9/2015
Hutchison China MediTech (Chi-Med) Release: Initiation Of Fruquintinib Phase III Registration Trial In Non-Small Cell Lung Cancer 12/8/2015
Boehringer Ingelheim Relesae: New Phase III Study Of Nintedanib In People With Systemic Sclerosis And Lung Fibrosis 12/8/2015
DBV Tech Announces Initiation Of Phase III Study Of Viaskin Peanut For The Treatment Of Peanut Allergic Children 12/8/2015
Amgen (AMGN) Submits Application In Europe To Expand Indication Of Kyprolis (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 12/7/2015
Atox Bio Enrolls First Patient In Phase III Study Of Potential Treatment For Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) 12/7/2015
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures 12/7/2015
TaiGen Biotechnology's Intravenous Taigexyn Successfully Achieved Primary Endpoint In Phase 3 Clinical Trial For Community Acquired Pneumonia 12/3/2015
Nuvo Research (NRI.TO) Provides Update on Pennsaid® 2% Phase 3 Clinical Trial 12/3/2015
Acacia Pharma: Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman 12/3/2015
OncoGenex (OGXI) Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses 12/2/2015
Janssen Biotech Inc. (JNJ) Submits Applications Seeking Approval Of STELARA In United States And European Union For Crohn's Disease 11/30/2015
AEterna Zentaris (AEZS) Affirms Fundamental Strength Of Business 11/30/2015
Otic Pharma Appoints Keith A. Katkin As Chairman Of The Board Of Directors 11/30/2015
Can-Fite BioPharma (CFBI) Reports Financial Results For Nine Months Ended September 30, 2015 11/30/2015
Regeneron (REGN) And Sanofi (SNY) Announce 18,000-Patient ODYSSEY OUTCOMES Trial Of Praluent Injection Fully Enrolled 11/24/2015
NovoCure Release: New Phase 3 Data Show Optune In Combination With Second Line Chemotherapy Is Superior To Second Line Chemotherapy Alone In Glioblastoma Patients At First Recurrence 11/23/2015
Amgen (AMGN) Release: European Commission Approves Kyprolis (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma 11/20/2015
AEterna Zentaris (AEZS) Announces First Patient Enrolled For Confirmatory Phase 3 Trial Of Macrilen For The Evaluation Of AGHD 11/19/2015
Teva (TEVA) Reports Positive Top-Line Results From Phase III Trials Evaluating Fluticasone Propionate/Salmeterol And Fluticasone Propionate Multidose Dry Powder Inhalers (Mdpis) In Patients With Asthma 11/19/2015
Morphotek Inc. Announces Collaboration Agreement With University of Gothenburg To Develop Farletuzumab, An Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, For Alpha-Particle Radioimmunotherapy In Ovarian Cancer 11/17/2015
Vectura Group plc (VEC.L) Release: FLAME Study Shows Superiority Of Novartis AG (NVS)’ Ultibro Breezhaler Over Seretide In Reducing COPD Exacerbations 11/17/2015
Protalix Biotherapeutics, Inc. (PLX) To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-Of-Phase II Meeting With FDA 11/16/2015
Allergan (AGN) Presents EARLY Analysis Data At The American Academy of Ophthalmology Annual Meeting 11/13/2015
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) Announces Positive Results From Pivotal Clinical Trial Of Seciera (OTX-101) In Dry Eye Disease 11/13/2015
NeuroDerm (NDRM) Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease 11/11/2015
Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK)'s Lupus Drug Also Performs Well in Late Stage Study 11/11/2015
Albireo Announces The Initiation In Japan Of A Phase III Clinical Trial Of Elobixibat In Chronic Constipation By Ajinomoto 11/10/2015
Teva (TEVA) Snags Breakthrough Therapy Designation from the FDA for Huntington's Disease Drug 11/9/2015
Regeneron (REGN) And Sanofi (SNY) Present Results From Pivotal Phase 3 Study Of Sarilumab At American College of Rheumatology Annual Meeting 11/9/2015
Samsung Bioepis' SB4 And SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles In One-Year Phase 3 Clinical Studies 11/9/2015
Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates 11/9/2015
BiondVax Pharmaceuticals Announces Third Quarter 2015 Financial Results And Update 11/9/2015
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib U.S. Clinical Trials 11/6/2015
AEterna Zentaris (AEZS) Reports Third Quarter Financial And Operating Results 11/6/2015
OncoGenex (OGXI) To Present At The Stifel 2015 Healthcare Conference 11/6/2015
Nuvo Research (NRI.TO) Announces Successful Pennsaid2% Phase 3 Trial For Russia 11/5/2015
Axovant (AXON) To Present At Upcoming Investor Conferences 11/5/2015
Merck KGaA (MKGAF.PK) And Pfizer (PFE) Announce Initiation Of Phase III First-Line Trial Of Avelumab In Patients With Recurrent Or Stage IV Non-Small Cell Lung Cancer 11/4/2015
Sinovac Biotech Ltd. (SVA) To Participate In Morgan Stanley Asia Pacific Summit 11/4/2015
Positive Late-Stage Data Leads Alkermes (ALKS) to Believe it Can File an NDA for ALKS 8700 in 2018 10/29/2015
Shire (SHPG) CEO Believes Dry Eye Drug Will Boost Its Chances of Landing Baxalta (BXLT) 10/28/2015
Macrocure (MCUR) Stock Plunges 63% as Lead Drug Fails Phase III Study 10/28/2015
Transition Therapeutics (TTH.TO) Announces Presentation Of ELND005 Phase 2/3 Clinical Study Results At Clinical Trials In Alzheimer's Disease (CTAD) Conference 10/28/2015
GlaxoSmithKline (GSK)'s Heart Drug Losmapimod Flunks Phase III Trial 10/27/2015
GW Pharma (GWPH)'s Sativev Disappoints in Two Late-Stage Cancer Pain Trials 10/27/2015
Norgine Presents Phase III Study Design For NER1006, Its Low-Volume Bowel Cleansing Solution, At United European Gastroenterology Week 2015 10/27/2015
Resverlogix (RVX.TO) Commences Phase 3 Clinical Trial BETonMACE With Apabetalone 10/26/2015
Boehringer Ingelheim Release: New Analyses Showed Consistent Efficacy of OFEV (nintedanib) Across Various Patient Populations With Idiopathic Pulmonary Fibrosis (IPF) 10/26/2015
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On November 2-5, 2015 In Munich, Germany 10/26/2015
ImmunoGen (IMGN), Roche (RHHBY)'s Kadcyla Flunks Late-Stage Study 10/23/2015
Ipsen (IPN.PA) Presents Additional Results From A Phase III Clinical Trial Of The Investigational Use Of Dysport® In Children With Spastic Equinus Foot Deformity Due To Cerebral Palsy 10/23/2015
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015
Gilead (GILD)'s New HIV Drug Genvoya Shows Lower Side-Effects Over Longer Term in Two Late-Stage Studies 10/22/2015



//-->